The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA

Stephen C Becker1, Juli Foster-Frey, David M Donovan

  • 1Animal Biosciences and Biotechnology Laboratory, Animal and Natural Resources Institute, Agricultural Research Service-U.S. Department of Agriculture, Beltsville Agricultural Research Center, 10300 Baltimore Avenue, Beltsville, MD 20705, USA.

Insights

LysK and lysostaphin are potent antimicrobial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). Optimal conditions for LysK were identified, and the study found these agents work synergistically to combat MRSA infections.

Area of Science:

  • Microbiology
  • Biochemistry
  • Antimicrobial Research

Background:

  • Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA), poses a significant public health threat.
  • Bacteriophage endolysins like LysK and bacteriocins like lysostaphin are promising alternatives to conventional antibiotics.
  • Previous research indicated that both LysK and lysostaphin can lyse MRSA cells.

Purpose of the Study:

  • To determine the optimal reaction conditions for recombinant His-tagged LysK protein activity.
  • To establish the minimum inhibitory concentration (MIC) of C-His-LysK.
  • To investigate the potential synergistic antimicrobial activity between LysK and lysostaphin against MRSA.

Main Methods:

  • Recombinant His-tagged LysK protein was purified and its enzymatic activity was assessed under varying pH and NaCl concentrations.
  • The minimum inhibitory concentration (MIC) of C-His-LysK was determined using standard microbiological assays.
  • A checkerboard assay was employed to evaluate the synergistic antimicrobial effects of LysK and lysostaphin in combination.

Main Results:

  • Optimal activity for recombinant His-tagged LysK was observed within a pH range of 6-10 and a NaCl concentration of 0.3-0.5 M.
  • The MIC of C-His-LysK was determined to be 32.85 ± 4.87 µg/mL.
  • The checkerboard assay demonstrated a synergistic antimicrobial effect when LysK and lysostaphin were used in combination against MRSA.

Conclusions:

  • LysK exhibits optimal enzymatic activity under specific biochemical conditions (pH 6-10, 0.3-0.5 M NaCl).
  • LysK and lysostaphin exhibit significant antimicrobial synergy, offering a potential strategy for enhanced MRSA treatment.
  • The findings support the development of LysK and lysostaphin as a dual-action therapeutic approach against MRSA infections.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Lysogenic Cycle of Bacteriophages00:43

Lysogenic Cycle of Bacteriophages

In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...
DNA Bacteriophages01:26

DNA Bacteriophages

Bacteriophages, or phages, are viruses that specifically infect bacteria, utilizing their genetic material to hijack host cellular machinery for replication. DNA bacteriophages employ single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) genomes. These phages exhibit diverse replication strategies and host interactions, influencing their ecological roles and applications in biotechnology and medicine.ssDNA BacteriophagesssDNA phages, with their small genomes, utilize unique strategies to...